pe26 schreef op 8 december 2015 10:43:
De woorden van de CEO 13 november erbij met betrekking tot Crohn resultaten.
FITZROY the studying Crohn’s: how important this is in the partnership discussions? It is quite important, Crohn’s is a very important disease and if the molecule will work in Crohn’s is very likely that is also will work in ulcerative colitis so the other large IBD disease
and in Crohn’s there hadn’t been a small molecule approved yet, this filgotinib would be the first JAK that moves into Phase 3 for Crohn’s we just very, very exciting it is thanks to our JAK1 selectivity that we believe filgotinib has an excellent proposition there for these patients because if the hemoglobin increases these patients often suffer from anemia.
So we are quite bullish about the commercial opportunity for Crohn’s disease products here and the partners see that likewise.Toen 13/11 was er grote inzicht in ruwe data en partners zien nadrukkelijk een commerciële meerwaarde voor Crohn.
Eens zien hoe dat zich uit in het Partnership.